ESIH:XETRA:XETRA-iShares MSCI Europe Health Care Sector UCITS ETF (EUR)

ETF | Others |

Last Closing

USD 6.84

Change

-0.03 (-0.49)%

Market Cap

USD 0.58B

Volume

0.01M

Analyst Target

N/A
Analyst Rating

Verdict

ducovest Verdict

Verdict

About

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2024-05-03 )

Largest Industry Peers for Others

Symbol Name Price(Change) Market Cap
XM1D:XETRA Xtrackers MSCI Japan UCITS ETF..

+0.02 (+0.04%)

USD 448.39B
LCUJ:XETRA Lyxor Core MSCI Japan (DR) UCI..

N/A

USD 191.96B
PRAJ:XETRA Amundi Index Solutions - Amund..

+0.01 (+0.04%)

USD 177.46B
PR1J:XETRA Amundi Prime Japan UCITS ETF D..

+0.07 (+0.26%)

USD 177.46B
XDJP:XETRA Xtrackers Nikkei 225 UCITS ETF..

-0.11 (-0.46%)

USD 157.79B
TM5:XETRA T-MOBILE US INC.DL-00001

+0.50 (+0.33%)

USD 126.93B
JARI:XETRA Amundi Index Solutions - Amund..

+0.04 (+0.08%)

USD 102.57B
8R80:XETRA Amundi Index Solutions - Amund..

+0.08 (+0.06%)

USD 102.14B
UIM5:XETRA UBS (Lux) Fund Solutions - MSC..

+0.01 (+0.02%)

USD 85.64B
SXR8:XETRA iShares Core S&P 500 UCITS ETF..

-2.28 (-0.44%)

USD 80.38B

ETFs Containing ESIH:XETRA

N/A

Market Performance

  Market Performance vs. Industry/Classification (Others) Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain 7.95% 71% C- 70% C-
Dividend Return N/A N/A N/A N/A N/A
Total Return 7.95% 71% C- 70% C-
Trailing 12 Months  
Capital Gain 5.62% 41% F 46% F
Dividend Return N/A N/A N/A N/A N/A
Total Return 5.62% 41% F 45% F
Trailing 5 Years  
Capital Gain N/A N/A N/A N/A N/A
Dividend Return N/A N/A N/A N/A N/A
Total Return N/A N/A N/A N/A N/A
Average Annual (5 Year Horizon)  
Capital Gain 3.29% 47% F 46% F
Dividend Return 3.29% 46% F 44% F
Total Return N/A N/A N/A N/A N/A
Risk Return Profile  
Volatility (Standard Deviation) 5.38% 82% B 86% B+
Risk Adjusted Return 61.25% 75% C 77% C+
Market Capitalization 0.58B 70% C- 62% D

Annual Financials (EUR)

Quarterly Financials (EUR)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
Superior risk adjusted returns

This stock has performed well, on a risk adjusted basis, compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile.

Low volatility

The stock’s annual returns have been stable and consistent compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile. Although stability is good, also keep in mind it can limit returns.

What to not like:
Below median dividend returns

The company’s average income yield over the past 5 years has been low compared to its peers. However, it is not a problem if you are not looking for income.